Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.34 |
| ▸ | CTSK | P43235 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805226 | 0.89 | C3AR1 (0.43) | C3AR1LMNAALDH1A1L3MBTL1HSD17B10 | |
| SCHEMBL800930 | 0.86 | C3AR1 (0.47) | C3AR1LMNAABCB1ALDH1A1HSD17B10 | |
| SCHEMBL800932 | 0.85 | PPARA (0.44) | C3AR1LMNAABCB1TSHRMEN1 | |
| SCHEMBL800482 | 0.82 | C3AR1 (0.46) | C3AR1LMNAABCB1ALDH1A1HSD17B10 | |
| SCHEMBL800915 | 0.77 | C3AR1 (0.46) | C3AR1LMNAABCB1ALDH1A1L3MBTL1 | |
| SCHEMBL800750 | 0.77 | C3AR1 (0.46) | C3AR1LMNAABCB1ALDH1A1L3MBTL1 | |
| SCHEMBL22636243 | 0.77 | C3AR1 (0.59) | C3AR1LMNAABCB1ALDH1A1HSD17B10 | |
| SCHEMBL22636241 | 0.77 | C3AR1 (0.59) | C3AR1LMNAABCB1ALDH1A1HSD17B10 | |
| SCHEMBL800967 | 0.76 | C3AR1 (0.47) | C3AR1LMNAABCB1ALDH1A1L3MBTL1 | |
| SCHEMBL10045823 | 0.76 | C3AR1 (0.49) | C3AR1LMNAABCB1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729060-B2 | Macrocyclic polyoxazole compounds and use thereof | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-05-20 | — | — | US | disclosed |
| US-8518928-B2 | Therapeutic compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120071527-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071527-A1 | THERAPEUTIC COMPOUNDS | TOP2B, DDB1, TOP1 | C3AR1 2841/4885LMNA 442/4885ABCB1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.